Thymosin Alpha-1 Plus Famciclovir Activates T-Cell Responses in Immune-Tolerant Hepatitis B Patients
Combination thymosin alpha-1 + famciclovir induced HBeAg seroconversion in some immune-tolerant chronic hepatitis B patients by activating HBV-specific T-cell responses — a population that usually doesn't respond to treatment.
Quick Facts
What This Study Found
Thymosin alpha-1 + famciclovir combination activated HBV-specific T-cell responses and achieved HBeAg seroconversion in some immune-tolerant chronic hepatitis B patients — a typically treatment-unresponsive population.
Key Numbers
How They Did This
Clinical trial in immune-tolerant chronic HBV patients (high HBV DNA, normal ALT). Combined thymosin alpha-1 + famciclovir therapy. HBeAg seroconversion, HBV DNA levels, and HBV-specific T-cell responses monitored.
Why This Research Matters
Immune-tolerant HBV carriers are the largest reservoir of the virus. If their immune tolerance can be broken with combination therapy, HBV global elimination becomes more achievable.
The Bigger Picture
Breaking immune tolerance in chronic HBV is the holy grail of hepatitis B therapy. Thymosin alpha-1's immune-activating properties combined with an antiviral that reduces viral load may create a window for immune reconversion.
What This Study Doesn't Tell Us
Small study with limited seroconversion rate details. Immune-tolerant HBV is heterogeneous. Long-term durability of seroconversion not established.
Questions This Raises
- ?Can thymosin alpha-1 break immune tolerance when combined with newer HBV antivirals?
- ?What predicts which immune-tolerant patients will respond?
- ?Should thymosin alpha-1 be combined with checkpoint inhibitors for HBV?
Trust & Context
- Key Stat:
- Tolerance broken In immune-tolerant HBV patients who typically ignore the virus, thymosin alpha-1 + famciclovir activated specific anti-HBV T-cells — breaking immune silence
- Evidence Grade:
- Moderate evidence from a clinical trial in the relevant (and most difficult to treat) HBV population, showing both immunological and virological responses.
- Study Age:
- Published in 2002. Thymosin alpha-1 combined with antivirals remains an active area of HBV cure research.
- Original Title:
- Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
- Published In:
- Journal of viral hepatitis, 9(4), 280-7 (2002)
- Authors:
- Lau, G K K, Nanji, A, Hou, J, Fong, D Y T, Au, W-S, Yuen, S-T, Lin, M, Kung, H-F, Lam, S-K
- Database ID:
- RPEP-00742
Evidence Hierarchy
Frequently Asked Questions
What is immune-tolerant hepatitis B?
About 90% of people infected at birth develop immune tolerance — their immune system 'ignores' the virus. They carry high viral loads but don't clear the virus because their T-cells don't respond to it.
Why is breaking tolerance important?
Immune-tolerant carriers are the largest HBV reservoir globally. If their immune systems can be activated to fight the virus (like this study shows), it could lead to a functional cure for chronic hepatitis B.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00742APA
Lau, G K K; Nanji, A; Hou, J; Fong, D Y T; Au, W-S; Yuen, S-T; Lin, M; Kung, H-F; Lam, S-K. (2002). Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.. Journal of viral hepatitis, 9(4), 280-7.
MLA
Lau, G K K, et al. "Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.." Journal of viral hepatitis, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin-alpha1 and famciclovir combination therapy activate..." RPEP-00742. Retrieved from https://rethinkpeptides.com/research/lau-2002-thymosinalpha1-and-famciclovir-combination
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.